Supplement of Omega-3 (Rich in Highly Bioavailable DHA/EPA) and Vitamins A, B_1 , B_2 , B_6 , B_{12} and D_3

Active ingredients (per ml):

Omega-3*	283,2 mg
DHA (21-23%*)	190,8 mg
EPA (5-7%*)	51,0 mg
Other Omega-3*	41,4 mg
Vitamin A*	1.737 UI
Vitamin B ₁	0,93 mg
Vitamin B ₂	1,18 mg
Vitamin B ₆	1,18 mg
Vitamin B ₁₂	2,11 mcg
Vitamin D ₃ *	34 UI
*Variable quantity because of being a natural product.	



Analytical constituents: Crude oils and fats 99.54%; moisture 0.2%; crude protein 0.0%; crude fibre 0.0%; crude ash 0.0%.

Mechanism of action:

- Both fats as well as oils are made up of a mixture of fatty acids. Polyunsaturated fatty acids are also known as Essential Fatty Acids (EFA) because they cannot be synthesized by the body and must, therefore, be supplied through the diet.
- There are two types of EFAs: Omega-3 (ALA, DHA, EPA...) and Omega-6 (LA, AA...). Cold-water fish
 are the richest natural source of Omega-3, particularly DHA and EPA. There are sources from plants
 such as linseed oil, but these are rich in ALA. Dietary ALA must be transformed by the body into biologically active DHA and EPA Omega-3, however, this bioconversion is very inefficient: in people the conversion from ALA to DHA and EPA is less than 0.10% and 10% respectively (Williams and Burdge, 2006),
 consequently, products rich in DHA and EPA are the best option.
- Omega-6 has been called "bad Omega" because the eicosanoids (prostaglandins, thromboxanes and leukotrienes) therein derived show pro-inflammatory activity, while the activity of Omega-3 is anti-inflammatory. This does not imply that Omega-6 should be eliminated from the diet, but there should be an appropriate ratio between the two. In modern human and animal diets this ratio is very biased towards Omega-6 and this imbalance may favour certain pathologies such as osteoarthritis, atherosclerosis, asthma, cancer, neurological and behavioural disorders etc. On increasing Omega-3 intake, EPA competes as a substrate for enzymes in the arachidonic acid cascade (AA, an Omega-6 precursor of the destructive eicosanoids) and this abundance of Omega-3 can replace the destructive subtype AA products in favour of the protective (Robinson and Stone, 2006).
- 60% of brain structure is lipid in nature. Among the EFAs, DHA is one of the most abundant in neuronal tissues: it is vital for the cerebral, cognitive and visual development of the foetus and young animal as well as for the maintenance and restoration of neuronal membrane function. As the animal ages, DHA deficiency may speed up mental decline.
- During pregnancy in dogs, DHA and EPA contribute to an optimal development of the foetus, they
 prevent defects and act on the central nervous system of the embryo. It has been proven that puppies
 of mothers with high levels of DHA are more intelligent and easier to train than normal puppies (Heinemann and Bauer, 2006; Zicker et col., K.M., 2012).



Data Sheet



Features

Neuroprotective action against neurodegenerative diseases such as cognitive dysfunction syndrome.

Preserves the physical, mental and sensory activity of older animals.

Supportive therapy in spinal cord injuries and other neurological disorders.

Promotes the cerebral and visual development, memory and learning of the foetus and newborn.

Reduces pain and inflammation in joints, tendons and muscles.

Very safe - Ideal for extended treatment.

Patented Omega-3 cold extraction method - Maximum bioactivity.

Highly palatable oil - Facilitates daily intake.

Available exclusively through veterinarians.

Developed and manufactured in Spain.



Supplement of Omega-3 (Rich in Highly Bioavailable DHA/EPA) and Vitamins A, B_1 , B_2 , B_6 , B_{12} and D_3

- Preliminary studies in dogs using a combination of DHA and cerebral phospholipids showed a trend toward improvement in memory capacity and a significant improvement in quality of life (Studzinski, under preparation).
- Omega-3 is prescribed more and more frequently in people for the long-term management of psychiatric and mental disorders: depression, bipolar disorder and schizophrenia. It is also recommended for attention deficit disorder, borderline personality disorder, dyslexia and cognitive impairment.
- Research trials for Alzheimer's disease in rodents have proven that DHA has anti-inflammatory properties and reduces amyloid levels and plaque formation (Horrocks and Yeo, 1999; Lim et al., 2003).
- Other studies conclude that DHA is required for maintaining the normal function of brain cells and that a deficiency in elderly people may contribute to cognitive impairment (Lim et al., 2003; Kalmijn et al., 1997; Horrocks and Yeo, 1999).
- In arthritis and other inflammatory diseases DHA and EPA alter prostaglandin production and thereby reduce some forms of inflammation. They have been tested with considerable success (especially in the early stages of the disease) in treating the symptoms of rheumatoid arthritis, and although they probably do not slow the progression of the disease itself, they very satisfactorily moderate the symptoms. The anti-inflammatory effects of EPA and DHA have also been studied for the treatment of Crohn's disease, Lupus and allergies, with positive results although evidence is very limited.
- Studies in rodents suggest that EPA prevents muscular damage by inhibiting the cyclooxygenase pathway (Jackson et al., 1988; Tisdale, 1996).
- Other benefits of EFAs:
- Cardiovascular: Omega-3 reduces triglyceride levels, raises HDL ("good cholesterol") levels and possibly lowers blood pressure.
- Renal disease: various studies have proven that EFAs reduce the progression of chronic renal disease, particularly at the glomerular level, reducing the proteinuria.
- Cancer: It has been shown that EFAs significantly prolong survival in dogs with lymphoma.
- Vitamin A contributes to normal iron metabolism, maintaining natural protective barriers such as the skin and mucous membranes, the normal functioning of the immune system and, together with DHA, to proper maintenance of vision.
- B group vitamins have neuroprotective effects and antioxidant properties, as well as the ability to normalise neurotransmitter levels. Vitamins B₂, B₆ and B₁₂ help improve concentration in situations of tiredness and fatigue.
- Vitamin D₃ is essential for the normal use and absorption of calcium and phosphorus, it contributes to bone, dental and muscular health and to the optimal functioning of the immune system.

Indications: Improves the functioning of the central and peripheral nervous system, vision, and musculoskeletal system. Indicated in older cats and dogs to encourage physical, mental and sensory activity, as well as to alleviate the effects of ageing on the animal's cognitive function, behaviour, mobility and quality of life. Also indicated as a supportive therapy in spinal cord injuries, neurological disorders and degenerative processes of the nervous tissue. In pregnant and lactating females it favours the cerebral and visual development of the foetus and newborn, it enhances memory and facilitates learning.

Directions of use: Shake before use. Administer by mixing it with feed or orally through a syringe. Daily dose:

- Initial (10 days), 2ml/5kg.
- Maintenance 1ml/5kg.

The effects of CONECTA® start to be seen after 3-4 weeks of application.







Data Sheet



Supplement of Omega-3 (Rich in Highly Bioavailable DHA/EPA) and Vitamins A, B_1 , B_2 , B_6 , B_{12} and D_3

Manufacture and the Environment:

- The Omega-3 in the CONECTA® formula is obtained through an exclusive patented method; 100% natural cold extraction which keeps the DHA and EPA molecular structures intact, thus ensuring their maximum bioavailability and bioactivity. Other products use boiling processes at high temperatures or chemical solvents for extracting fish oil.
- · CONECTA® is 100% environmentally friendly as it does not generate waste,
- making good use of all the raw material used.
- CONECTA® is manufactured in a pharmaceutical grade plant in Galicia...

Safety: CONECTA® has no contraindications and can be taken long-term or for life.

Warnings: Keep the container tightly closed in a cool (15-20°C), dry place away from direct sunlight and out of reach of children and animals. Liquid at room temperature, it may form precipitates if refrigerated. Due to being an oily product it may experience minor expansions and/or contractions during transport, causing minor losses or deformations of the container.

Presentation: 135 ml.

Supporting materials:

- Magazine advertising
- · Compilation of abstracts from published research articles

Bibliography:

- Agostoni, C., Trojan, S., Bellu, R., Riva, E., Bruzzese, M.G., Giovannini, M. Developmental quotient at 24 months and fatty acid composition of diet in early infancy: follow up study. Arch Dis Chil 1997;76:421-424.
- Aguado Acín, M.P. Vitamina D y osteoporosis. ¿Es suficiente tomar el sol? Rev Esp Reumatol 2001;28:101-105.
- Angerer, P., Von Schacky. Ω-3 polyunsaturated fatty acids and the cardiovascular system. Curr Opin Lipidol 2000;11:57-63.
- Bahadori, B., Uitz, E., Thonhofer, R., Trummer, M., Pestemer-Lanch, I., McCarty, M., Krejs, G.J. Omega-3 fatty acids infusions as adjuvant therapy in rheumatoid arthritis. JPEN J Parenter Enteral Nutr 2010;34:151-155.
- Bazan, N.G. Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci 2006; 29: 263-271.
- Burr, G.O., Burr, M.M. On the nature and role of fatty acids essential in nutrition. J Biol Chem 1930; 86: 587-621.
- Calder, P.C. Polyunsaturated fatty acids, inflammatory processes and autoimmune diseases. Mol Nutr Food Res 2008;52(8):885-897.
- Calon, F., Cole, G. Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins Leukot Essent Fatty Acids 2007; 77: 287-293.
- Cardo, E., Servera, M. Trastorno por déficit de atención/hiperactividad: estado de la cuestión y futuras líneas de investigación. Rev Neurol 2008;46(6):365-372.
- Cleland, L.G., French, J., Betts, H.W., Murphy, G.A., Elliott, M.J. Clinical and biochemical effects of dietary fish oil supplements in rheumatoid arthritis, J Rheumatol 1988;15:1471-1475.
- Gil-Campos, M., Dalmau Serra, J., Comité de Nutrición de la Asociación Española de Pediatría. Importancia del ácido docosahexaenoico (DHA): funciones y recomendaciones para su ingesta en la infancia. An Pediatr (Barc) 2010;73(3):142.e1-142.e8.
- Guadalix, S., Jódar, E. Vitamina D y función muscular. Rev Esp Enferm Metab Oseas. 2007;16(2):41-44.
- Hawkins Carranza, F. La vitamina D3 y el hueso. Rev Esp Enferm Metab Oseas. 2007;16(3):45-47.
- Heinemann, K.M., Bauer, J.E. Docosahexaenoic acid and neurologic development in animals. J Am Vet Med Assoc. 2006 Mar 1;228(5):700-5, 655.



Data Sheet





Supplement of Omega-3 (Rich in Highly Bioavailable DHA/EPA) and Vitamins A, B₁, B₂, B₆, B₁₂ and D₃

- Horrocks, L.A., Farooqui, A.A. Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 361-372.
- Horrocks, L.A., Yeo, Y.K. Health benefits of docosahexaenoic acid (DHA). Pharmacol Res. 1999 Sep;40(3):211-25.
 Hurst, S., Zainal, Z., Caterson, B., Hughes, C.E., Harwood, J.L. Dietary fatty acids and arthritis. Prostaglandins
- Hurst, S., Zainai, Z., Caterson, B., Hugnes, C.E., Harwood, J.L. Dietary fatty acids and artifitis. Prostagiand Leukot Essent Fatty Acids 2010;82:315-318.
- Innis, S. Dietary (n-3) fatty acids and brain development. J Nutr 2007;137:855-859.
- Jackson, M.J., Roberts, J., Edwards, R.H. Effects of dietary-fish-oil feeding on muscle growth and damage in the rat. Br J Nutr. 1988 Sep;60(2):217-24.
- Kalminj, S., Van Boxtel, M.P.J., Ocke, M., Verschuren, W.M.M., Kromhout, D., Launer, L.J. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology. 2004 Jan 27;62(2):275-80.
- Lim, S.Y., Hoshiba, J., Moriguchi, T., Salem, N. Jr.N-3 fatty acid deficiency induced by a modified artificial rearing method leads to poorer performance in spatial learning tasks. Pediatr Res. 2005 Oct;58(4):741-8.
- Lim, S.Y., Hoshiba, J., Salem, N. Jr. An extraordinary degree of structural specificity is required in neural phospholipids for optimal brain function: n-6 docosapentaenoic acid substitution for docosahexaenoic acid leads to a loss in spatial task performance. J Neurochem. 2005 Nov;95(3):848-57.
- Lim, S.Y., Suzuki, H. Dose-response effect of egg-phosphatidylcholine on maze-learning ability and fatty acid composition of plasma and brain in aged mice fed an n-3 fatty acid-deficient diet. Ann Nutr Metab. 2002;46(5):215-21.
- Lim, S.Y., Suzuki, H. Dose-response effect of docosahexaenoic acid ethyl ester on maze behavior and brain fatty acid composition in adult mice. Int J Vitam Nutr Res. 2002 Mar;72(2):77-84.
- Lim, S.Y., Suzuki, H. Changes in maze behavior of mice occur after sufficient accumulation of docosahexaenoic acid in brain. J Nutr. 2001 Feb;131(2):319-24.
- Lim, S.Y., Suzuki, H. Effect of dietary docosahexaenoic acid and phosphatidylcholine on maze behavior and fatty acid composition of plasma and brain lipids in mice. Int J Vitam Nutr Res. 2000 Sep;70(5):251-9
- Lim, S.Y., Suzuki, H. Intakes of dietary docosahexaenoic acid ethyl ester and egg phosphatidylcholine improve maze-learning ability in young and old mice. J Nutr. 2000 Jun;130(6):1629-32.
- Mayurasakorn, K., Williams, J.J., Ten, V.S., Deckelbaum, R.J. Docosahexaenoic acid: brain accretion and roles in neuroprotection after brain hipoxia and ischemia. Curr Opin Clin Nutr Metab Care 2011; 14: 158-167.
- McCann, J.C., Ames, B.N. Is Docosahexaenoic acid, an n-3 long-chain polyunsaturated fatty acid, required for development of normal brain function? An overview of evidence from cognitive and behavioral tests in humans and animals. Am J Clin Nutr 2005; 82: 281-295.
- Mesa García, M.D., Aguilera García, C.M., Gil Hernández, A. Importancia de los lípidos en el tratamiento nutricional de las patologías de base inflamatoria. Nutr Hosp. 2006; 21(2): 30-43.
- Morris, M.C., Evans, D.A., Bienias, J.L. y cols. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003; 60: 940-946.
- Nussbaum, R.L. and Ellis C.E. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003; 348: 1356-1364.
- Lama, R.A., Moráis, A. Las grasas en la alimentación infantil. Importancia de los ácidos grasos poliinsaturados. An Pediatr, Monogr 2005;3(1):16-23.
- Rueda, F., Domingo, J.C., Mach, N. Efectos de los ácidos grasos omega 3 y otros suplementos alimenticios en procesos patológicos relacionados con la tercera edad. Rev Esp Nutr Hum Diet. 2011;15(1):20-29.
- Sánchez, A., Puche, R., Zeni, S., Oliveri, B., Galich, A.M., Meffei, L., Plantalech, L., Poudes, G., Bregni, C. Papel del calcio y de la vitamina D en la salud ósea (Parte I). Rev Esp Enferm Metab Oseas. 2002; 11(6):201-217.
- Sanhueza, J., Nieto, S., Valenzuela, A. Ácido docosahexaenoico (DHA), desarrollo cerebral, memoria y aprendizaje: la importancia de la suplementación perinatal. Rev Chil Nutr 2004;31(2):84-92.
- Simopoulos, A.P. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002; 56: 365-379.
- Sinn, N., Bryan, D. Effect of Supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J Dev Behav Pediatr 2007;28:82-91.
- Soderberg, M., Edlund, C., Kristensson, K., Dallner, G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991; 26: 421-425.
- Studzinski, C.M., Araujo, J.A., Milgram, N.W. The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs. Prog Neuropsychopharmacol Biol





Data Sheet

VetNova

Supplement of Omega-3 (Rich in Highly Bioavailable DHA/EPA) and Vitamins A, B_1 , B_2 , B_6 , B_{12} and D_3

Psychiatry. 2005 Mar;29(3):489-98.

- Sontrop, L., Campbell, M.K. Omega-3 polyunsaturated fatty acids and depression: a review of the evidence and a methodological critique. Prev Med 2006; 42(1): 4-13.
- Stevens, L., Zentall, S., Deck, J., Abate, M., Watkins, B., Lipp, S. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr 1995;62:761-768.
- Tanskanen, A., Hibbeln, J.R., Tuomilehto, J., Uutela, A., Haukkala, A., Viinamäki, H., Lehtonen, J., Vartiainen, E. Fish consumption and depressive symptoms in the general population in Finland. Psychiatr Serv 2001; 52(4): 529-531.
- Tisdale, M.J. Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia. Nutrition. 1996 Jan;12(1 Suppl):S31-3
- Trebble, T.M., Wooten, S.A., Miles, E.A., Mullee, M., Arden, N.K., Ballinger, A.B., et al. Prostaglandin E2 production and T cell function after fish-oil supplementation: response to antioxidant co-supplementation. Am J Clin Nutr 2003;78:376-382.
- Tully, A.M., Roche, H.M., Doyle, R., Fallon, C., Bruce, I., Lawlor, B., et al. Low serum cholesteryl esterdocosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr 2003; 89: 483-489.
- Valenzuela, A., Nieto, S. Ácido docosahexaenoico (DHA) en el desarrollo fetal y en la nutrición materno-infantil. Rev Med Chil 2001;129:1203-1211.
- Valenzuela, A., Nieto, S. Ácidos grasos omega-6 y omega-3 en la nutrición perinatal: su importancia en el desarrollo del sistema nervioso y visual. Rev Chil Pediatr 2003;74(2):149-157.
- Valenzuela, A., Sanhueza, J., Nieto, S. Docosahexaenoic acid (DHA), essentiality and requirements: why and how to provide supplementation. Grasas & Aceites 2006;57:229-237.
- Valenzuela, A., Sanhueza, J. Aceites de origen marino; su importancia en la nutrición y en la ciencia de alimentos. Rev Chil Nutr 2009;36:246-257.
- Valenzuela, R., Tapia, G., González, M., Valenzuela, A. Ácidos grasos omega-3 (EPA y DHA) y su aplicación en diversas situaciones clínicas. Rev Chil Nutr 2011;3:356-367.
- Zicker, S.C., Jewell, D.E., Yamka, R.M., Milgram, N.W. Evaluation of cognitive learning, memory, psychomotor, immunologic, and retinal functions in healthy puppies fed foods fortified with docosahexaenoic acid-rich fish oil from 8 to 52 weeks of age. J Am Vet Med Assoc. 2012 Sep 1;241(5):583-94. doi: 10.2460/javma.241.5.583.

If you are interested in any of the articles listed, please do not hesitate to request them through the following contacts: vetnova@vetnova.net, +34 918 440 273, or your VetNova or Distributor Sales Representative.



Data Sheet



